Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial Evaluating the Efficacy of a Sequential Treatment Gemcitabine Plus Nab-paclitaxel (Gembrax) Followed by Folfirinox Versus Folfirinox Alone in Patients Treated in First Metastatic Line Pancreatic Cancer

NCT05065801 is registered in ClinicalTrials.gov with Institut du Cancer de Montpellier - Val d'Aurelle as lead sponsor.

NCT NCT05065801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05065801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial Evaluating the Efficacy of a Sequential Treatment Gemcitabine Plus Nab-paclitaxel (Gembrax) Followed by Folfirinox Versus Folfirinox Alone in Patients Treated in First Metastatic Line Pancreatic Cancer
Lead sponsor
Institut du Cancer de Montpellier - Val d'Aurelle
Phase
Phase 2
Overall status
Recruiting
Start date
January 11, 2022
Completion date
June 30, 2028
Enrollment
162 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer